Antapodia Therapeutics and Kupffer Biotherapeutics are subsidiaries of Stempodia Corporation, a science-driven biopharmaceutical startup providing breakthrough solutions for advanced and metastatic cancers. The company’s first-in-class invadopodia-targeted gene therapies have shown dramatic anti-metastasis efficacy and can be quickly moved to clinical trials. The company’s iKupffer technology solves multiple obstacles to develop first-in-class immune-cell therapies for desmoplastic GI cancers.